November 2020 // Investment

Synendos Therapeutics (Synendos), a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS) disorders, announced it has raised CHF 20 million in a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures and participation from BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors.


Download here below the full press release.

Synendos Series A financing 12 Nov 2020
Download • 159KB

Recent Posts

See All

April 2021 // Investment

Synendos Series A Extension Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capita

October 2020 // Funding

Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000).